Company intelligence / Profile preview

Imutec Pharma

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Imutec Pharma was a Canadian biopharmaceutical company focused on the development of immunotherapies for cancer treatment. Its lead product candidate, Virulizin, was a biological response modifier derived from bovine bile that aimed to stimulate the immune system to fight solid tumors, particularly pancreatic cancer. The company was publicly traded on the Toronto Stock Exchange before undergoing a corporate reorganization and name change to Lorus Therapeutics in 2000. This entity eventually evolved into Aptose Biosciences, shifting its focus toward small molecule therapeutics for hematologic malignancies.

Therapeutic areas: Oncology
Modalities: Biologic
Industry: Biotech

Beyond the preview

Go deeper on Imutec Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imutec Pharma.

Explore the full profile